Premium
The Medtronic Intact Bioprosthesis: Clinical and Hemodynamic Performance Over 13 Years
Author(s) -
De La Fuente Anselmo,
Sánchez José Ramón,
Fernández Juan Luis,
Romero Javier,
Berjon Jesús,
Moriones Ignacio
Publication year - 2002
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1046/j.1525-1594.2002.06984.x
Subject(s) - medicine , hemodynamics , surgery , mortality rate , cardiology , aortic valve , aortic valve replacement , stenosis
We evaluated our results over 13 years with the aortic‐position Medtronic Intact bioprosthesis. Our study involved 91 consecutive patients with isolated aortic valve replacement with the Medtronic Intact bioprosthesis. The follow‐up was complete for 95%. Mean follow‐up was 6.61 years (range 16 days–13 years), 590 patient years. Early mortality rate was 3.3%. Late mortality was 23 patients. Survival at 13 years was 53.52% (SD = 7.63%). The linearized rate of major thromboembolism was 0.34% per patient year; rate of major bleeding events was 0.33% per patient year. The rate of nonstructural dysfunction was 0.16% per patient year. Rate of reoperation was 0.53% and rate of structural valve deterioration was 0.16% per patient year. New York Heart Association (NYHA) postoperative classes were I to II in 92.21%. Gradients were as follows: 21 to 23.87 mm Hg, 23 to 18 mm Hg, 25 to 15.5 mm Hg, and 27 to 16.50 mm Hg. Structural valve deterioration was low during the 13 years of follow‐up. Valve gradients and areas remained the same over the follow‐up period. The Medtronic Intact bioprosthesis shows excellent clinical and hemodynamic performance at 13 years of follow up.